Compare · BSX vs RMED
BSX vs RMED
Side-by-side comparison of Boston Scientific Corporation (BSX) and Ra Medical Systems Inc. (RMED): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and RMED operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $92.25B, about 13704.8x RMED ($6.7M).
- BSX has hit the wire 3 times in the past 4 weeks while RMED has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 1 for RMED).
- Company
- Boston Scientific Corporation
- Ra Medical Systems Inc.
- Price
- $62.06-5.52%
- $0.57+4.03%
- Market cap
- $92.25B
- $6.7M
- 1M return
- -11.05%
- -
- 1Y return
- -39.23%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 1
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Ra Medical Systems Inc.
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light and is used as a tool in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.
Latest BSX
- Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
- Boston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Boston Scientific announces results for first quarter 2026
- SEC Form EFFECT filed by Boston Scientific Corporation
- SEC Form 424B3 filed by Boston Scientific Corporation
- Boston Scientific downgraded by Raymond James with a new price target
- Boston Scientific announces conference call discussing first quarter 2026 results
- Amendment: SEC Form S-4/A filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Latest RMED
- SEC Form SC 13G filed by Ra Medical Systems Inc.
- Ra Medical Systems Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)
- Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)
- Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)
- SEC Form SC 13D/A filed by Ra Medical Systems Inc. (Amendment)
- Ra Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 4 filed by Thomassen Margrit
- SEC Form 4 filed by Francis, John P.
- New insider Francis, John P. claimed ownership of 2,611 shares (SEC Form 3)